David Clayton1, Farshid Faraji1, Douglas Arnold2, Alex De Crespigny3, Alexandre Coimbra3
1Genentech, Inc., South San Francisco, CA, United States; 2NeuroRX Research, Montreal, Quebec, Canada; 3Genentech Inc, South San Francisco, CA, United States
Several single site resting-state fMRI studies (RS-fMRI) have shown that brain functional connectivity metrics are altered in Alzheimer Disease (AD) patients. Exploratory RS-fMRI was included in two global Phase II studies of a novel AD drug. We report here fMRI data quality control procedures and observed quality metrics from screening and very early on-treatment scans. Subject tolerance and protocol compliance was good. In spite of heterogeneous scanning equipment and variable raw SNR across sites, the data pre-processing pipeline resulted in consistent processed data quality metrics, with few scans that could not be used for subsequent functional connectivity analysis.